Lupin Settles Patent Dispute With U.S. Makers Of Glumetza Diabetes Drug
This article was originally published in PharmAsia News
Lupin Pharmaceuticals agreed to a patent-settlement with two U.S.-based companies, Santarus and Depomed, giving Lupin a chance at an early launch of a generic of the diabetes drug, Glumetza (metformin).
You may also be interested in...
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.
A lower first dose boosted the vaccine’s efficacy result, but AstraZeneca has conceded that this has to be proven in a separate trial. In the meantime, the UK government has asked the regulator to assess the vaccine under a special health emergency provision.